Welcome to European Tribune. It's gone a bit quiet around here these days, but it's still going.
David Mitchell, founder of an advocacy group called Patients for Affordable Drugs, said in a statement that the $475,000 cost is "excessive" and claims the federal government spent $200 million in early research on CAR-T therapy before Novartis purchased rights to the treatment.
Free market in action, as usual.
by gk (gk (gk quattro due due sette @gmail.com)) on Thu Oct 5th, 2017 at 03:41:32 PM EST
[ Parent ]

Others have rated this comment as follows:


Occasional Series